Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Toni Braxton's 'He Wasn't Man Enough' has new life as Lifetime movie ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

Experience a 20-day survival challenge in the rainforest of Vietnam, where primitive skills and natural resources are ...

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

This encouraging oncology development arrives at a pivotal moment for Eli Lilly's primary revenue drivers. On November 17, 2025, its main competitor, Novo Nordisk, announced price reductions for its ...

Overture Life SLU secured CE mark certification for its Davitri system that automates the vitrification and thawing of oocytes and embryos, making the processes more efficient, consistent and ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and ...

The global anticancer drugs market size is calculated at USD 182.37 billion in 2025 and is expected to reach around USD ...

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...